Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines has received FDA approval for its TEVIMBRA-based regimen, which includes ZIIHERA and chemotherapy, aimed at treating adult patients with unresectable locally advanced or metastatic HER2-positive gastric and gastroesophageal junction cancer. This approval marks a significant advancement in the treatment options available for this patient population.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA approval signifies a major milestone for BeOne Medicines.
  • TEVIMBRA-based regimen offers a new treatment option for HER2+ GEA.
  • Combination therapy could improve outcomes for patients with advanced disease.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
Tislelizumab
Phase 2 · Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction

Frequently Asked Questions

What is TEVIMBRA used for?

TEVIMBRA is used in combination with ZIIHERA and chemotherapy for treating HER2+ gastric cancer.

Who approved the TEVIMBRA regimen?

The U.S. Food and Drug Administration (FDA) approved the TEVIMBRA regimen.

What type of cancer does the TEVIMBRA regimen target?

The regimen targets unresectable locally advanced or metastatic HER2-positive gastric cancer.

What does sBLA stand for?

sBLA stands for supplemental Biologics License Application.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines TEVIMBRA HER2-positive FDA approval gastric cancer
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TislelizumabPhase 2
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →